ВИРҮСТ ХЕПАТИТ, ЧИХРИЙН ШИЖИН ХАВСАРСАН ҮЕИЙН ЭЛЭГНИЙ БҮТЭЦ ҮЙЛ АЖИЛЛАГААНЫ ӨӨРЧЛӨЛТИЙГ M2BPGI БОЛОН ЭЛЭГНИЙ ЭДИЙН ШИНЖИЛГЭЭНИЙ ӨӨРЧЛӨЛТТЭЙ ХАРЬЦУУЛСАН ҮР ДҮН
- VernacularTitle:ВИРҮСТ ХЕПАТИТ, ЧИХРИЙН ШИЖИН ХАВСАРСАН ҮЕИЙН ЭЛЭГНИЙ БҮТЭЦ ҮЙЛ АЖИЛЛАГААНЫ ӨӨРЧЛӨЛТИЙГ M2BPGI БОЛОН ЭЛЭГНИЙ ЭДИЙН ШИНЖИЛГЭЭНИЙ ӨӨРЧЛӨЛТТЭЙ ХАРЬЦУУЛСАН ҮР ДҮН
- Author:
Altantuya I
1
;
Badamjav S
2
;
Sainbileg S
2
;
Uranbaigal E
2
;
Otgonbayar R
2
;
Bira N
2
;
Davaadorj D
2
Author Information
1. Mongolian National University of Medical Science
2. School of Medicine, MNUMS
- Publication Type:Journal Article
- Keywords:
Alaninaminotranspherasa, Aspartataminotranspherasa, Complete blood count, Mac-2 binding protein
- From:Innovation
2017;11(2):69-72
- CountryMongolia
- Language:Mongolian
-
Abstract:
BACKGROUND. The 84.4 percent of newly diagnosed patients with diabetes have obesity
in Mongolia. Nowadays, prevalence of obesity has increased steadily in Mongolia.
Diabetic patients with viral hepatitis has high risk of having liver cirrhosis. Therefore,
screening of fatty liver and liver fibrosis in diabetic patients is more important. The main
diagnosing method of fatty liver and liver fibrosis is liver biopsy and histology but so far,
we are able to detect viral infection using viral marker and determine fibrosis stage of
NAFLD in patients who has diabetes mellitus type 2. Using noninvasive method determining
liver fibrosis involve many researches to reveal new biomarkers and technics to
find out liver fibrosis. Japanese researchers has found The Wisteria floribunda agglutinin-
positive human Mac-2-binding protein (WFA+-M2BP) was recently shown to be a
liver fibrosis glycobiomarker with a unique fibrosis-related glycoalteration.This biomarker
helps to determine liver fibrosis stage in fatty liver disease and viral hepatitis. There is
no research to reveal viral infection, fatty liver and liver fibrosis in diabetic patients in
Mongolia, so far. So it is necessary to study revealing viral infection, fatty liver disease
and to determine stages of fibrosis using WFA+-M2BP to screen liver fibrosis in diabetic
patients. OBJECTIVE. To identify viral infection, HCV/HBV in patients with diabetes and
to compare liver function and diabetes control for diabetic patients with liver disease.
METHODS. We collect data from 25thNovember, 2015 to October of 2016. We got permission
of research from the patients by handwriting signature who diagnosed Diabetes
mellitus in National University Hospital. Haemotology, biochemistry test, coagulogramm,
immunology test are evaluated in 415 patients in clinical laboratory of National university
hospital. By the objective, the diabetes patients with viral hepatitis will attend
to second step of research. We used HISCL 5000 apparatus of Sysmex Japan to do
immunology tests. Also we use SPSS 19.0 and EXCEL program. RESULT. There were 294
patients and by WHO classification of ages 20-29 aged patient (n=4), 30-39 aged(n=19),
40-49 aged(n=65), 50-59 aged(n=126), 60-70 aged(n=48), over 70 aged(n=14)or
53.24±9.43. 146 patients are male,148 patients are female.By BMI 29.9±1.14.By blood
test, thrombocytes counted 256.6±11.7;in coagulogramm the prothrombin time was
111.7±31.4; in biochemistry test total bilirubin 16.46±10.6; AP 364.7±192.3;AST 35.7±45.7;
ALT 42.8±45.5; GGT 86.53±123.4;albumin 42.06±23.95;total cholesterol 6.04±2.47;triglyceride
5.72±34.5;HbA1c 8.83±5.92; in immunology testsanti-HCV 29.37±18.87 (n=58); HBsAg
590.134±1013.7 (n=23); M2BP (COI) counted 2.24±2.19. CONCLUSION. There were 58
diabetic patients with C viral infection and 23 diabetic patients with B viral infection.
By WFA+-M2BP glycobiomarker, we found that diabetic patients with viral hepatitis has
more liver fibrosis.
